WO2007124382A3 - Inhaled imipenem - Google Patents

Inhaled imipenem Download PDF

Info

Publication number
WO2007124382A3
WO2007124382A3 PCT/US2007/067002 US2007067002W WO2007124382A3 WO 2007124382 A3 WO2007124382 A3 WO 2007124382A3 US 2007067002 W US2007067002 W US 2007067002W WO 2007124382 A3 WO2007124382 A3 WO 2007124382A3
Authority
WO
WIPO (PCT)
Prior art keywords
imipenem
inhaled
relates
present
formulations containing
Prior art date
Application number
PCT/US2007/067002
Other languages
French (fr)
Other versions
WO2007124382A2 (en
Inventor
Johnny Lai
Ribhi Shawar
Original Assignee
Novartis Vaccines & Diagnostic
Johnny Lai
Ribhi Shawar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic, Johnny Lai, Ribhi Shawar filed Critical Novartis Vaccines & Diagnostic
Publication of WO2007124382A2 publication Critical patent/WO2007124382A2/en
Publication of WO2007124382A3 publication Critical patent/WO2007124382A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
    • C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
    • C07D477/20—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Abstract

The present invention relates to inhaled formulations containing imipenem for increased efficacy and decreased toxicity in treating microbial infections.
PCT/US2007/067002 2006-04-19 2007-04-19 Inhaled imipenem WO2007124382A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79369206P 2006-04-19 2006-04-19
US60/793,692 2006-04-19

Publications (2)

Publication Number Publication Date
WO2007124382A2 WO2007124382A2 (en) 2007-11-01
WO2007124382A3 true WO2007124382A3 (en) 2008-05-29

Family

ID=38625745

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/067002 WO2007124382A2 (en) 2006-04-19 2007-04-19 Inhaled imipenem

Country Status (1)

Country Link
WO (1) WO2007124382A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW465235B (en) 1998-09-17 2001-11-21 United Video Properties Inc Electronic program guide with digital storage
BRPI0616642A2 (en) 2005-09-29 2011-06-28 Nektar Therapeutics antibiotic formulations, unit doses, kits and methods
EP3007689B1 (en) 2013-01-10 2018-03-07 Pulmokine, Inc. Non-selective kinase inhibitors
CN104208046A (en) * 2013-05-29 2014-12-17 天津金耀集团有限公司 Carbapenem antibiotic inhalation preparation
CN104208075A (en) * 2013-05-29 2014-12-17 天津金耀集团有限公司 Compound inhalation preparation containing carbapenem antibiotic and glucocorticoid
CN106132403B (en) * 2013-10-11 2020-04-28 普尔莫凯恩股份有限公司 Spray-dried formulations
CA3041679A1 (en) 2016-10-27 2018-05-03 Lawrence S. ZISMAN Combination therapy for treating pulmonary hypertension
WO2021221101A1 (en) * 2020-04-30 2021-11-04 デンカ株式会社 Liquid formulation and pharmaceutical product containing cilastatin

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009126A1 (en) * 2002-03-05 2004-01-15 Transave, Inc. Inhalation system for prevention and treatment of intracellular infections
WO2004075874A1 (en) * 2003-02-28 2004-09-10 Anbics Patents-Licences Ag Method for treatment and prevention of acute and chronic pseudomonas aeruginosa airway infections with inhalable macrolides
US20060062738A1 (en) * 2004-01-27 2006-03-23 Thomas Hofmann Method for improvement of tolerance for therapeutically effective agents delivered by inhalation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009126A1 (en) * 2002-03-05 2004-01-15 Transave, Inc. Inhalation system for prevention and treatment of intracellular infections
WO2004075874A1 (en) * 2003-02-28 2004-09-10 Anbics Patents-Licences Ag Method for treatment and prevention of acute and chronic pseudomonas aeruginosa airway infections with inhalable macrolides
US20060062738A1 (en) * 2004-01-27 2006-03-23 Thomas Hofmann Method for improvement of tolerance for therapeutically effective agents delivered by inhalation

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BADIA JOAN R ET AL: "Disposition of instilled versus nebulized tobramycin and imipenem in ventilated intensive care unit (ICU) patients", JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, vol. 54, no. 2, August 2004 (2004-08-01), pages 508 - 514, XP002473338, ISSN: 0305-7453 *
FAWZIAH MARRA ET AL.: "Piperacillin/Tazobactam versus Imipenem: A double-blind, randomized formulary feasibility study at a major teaching hospital", DIAGN MICROBIOL INFECT DIS, 1998, pages 355 - 368, XP002473340 *
HASHIMOTO S. ET AL.: "Aerolization of imipenem/cilastatin prevents pseudomonas-induced acute lung injury", J. ANTIMICROBIAL CHEMOTHERAPY, vol. 38, 1996, pages 809 - 818, XP002473339 *
KATIYAR SK & S. PRAKASH: "Bio-availability of imipenum in bronchial epithelial lining fluid, alveolar macrophages and serum on administration via inhaled and intravenous route", NCCP YOUNG SCIENTIST AWARD SESSION, 23 November 2007 (2007-11-23), pages 41 - 42, XP002473341 *
RODLOFF A C ET AL: "Two decades of imipenem therapy", JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, vol. 58, no. 5, November 2006 (2006-11-01), pages 916 - 929, XP002473342, ISSN: 0305-7453 *

Also Published As

Publication number Publication date
WO2007124382A2 (en) 2007-11-01

Similar Documents

Publication Publication Date Title
WO2008030988A3 (en) Selectively targeted antimicrobial peptides and the use thereof
WO2006013441A3 (en) Use of probiotic bacteria for the preparation of topical compositions for skin protection
WO2007124382A3 (en) Inhaled imipenem
WO2007011962A3 (en) Treatment of cancer
WO2007130655A3 (en) Phage derived antimicrobial activities
WO2010090860A3 (en) Methods and compositions for treating bacterial infection
WO2008030883A3 (en) Treatment of cancer
WO2010003533A3 (en) Pyridopyrimidine compounds as anti-tubercular agents
MX2009006846A (en) Substituted tetracycline compounds.
WO2007146965A3 (en) Compounds for the treatment of periodontal disease
EP1868628A4 (en) Compounds, compositions and methods for the treatment of poxvirus infections
WO2007064872A3 (en) Urea compounds useful in the treatment of cancer
TW200734344A (en) Antibacterial agents
WO2008115281A3 (en) Compounds for treating viral infections
WO2007017267A3 (en) Novel compounds
WO2009077471A3 (en) Azolylmethyloxiranes, use thereof and agents containing the same
TW200630367A (en) Substituted adenines and the uses thereof
WO2006120563A3 (en) Antibacterial agents
WO2007070613A3 (en) Rifamycin analogs and uses thereof
IL187111A0 (en) Use of tfpi to treat severe bacterial infections
WO2007118130A3 (en) Antibacterial agents
WO2007059226A3 (en) Photoactivatable antimicrobial agents
WO2008132021A3 (en) Fungicide mixtures
WO2007144057A3 (en) Antimicrobial carbon
WO2007009701A3 (en) Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07760944

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 07760944

Country of ref document: EP

Kind code of ref document: A2